Barcelona-based venture capital firm Asabys Partners has taken a major step in advancing health technology innovation with the launch of its second fund, Sabadell Asabys Health Innovation Investments II (SAHII 2), targeting €200 million in commitments. The fund aims to support early-stage biotech, medtech, and digital health companies developing transformative solutions with strong scientific backing.
First Close at €100M, Targeting €200M by Year-End
Asabys announced the first close of SAHII 2 with €100 million in pledged capital, including significant contributions from Banc Sabadell, the firm’s anchor investor since its 2018 inception, and the Alantra Investment Pool. The fund’s remaining €100 million target is expected to be met by the end of 2026, according to the firm’s latest disclosure.
The new fund will focus on European startups in the biopharma, medical devices, and digital health sectors. Asabys plans to invest in 12–15 companies across the EU, UK, Israel, and the U.S., with a particular emphasis on Spain. The firm’s strategy spans from early-stage research to commercialization, reflecting its hybrid investment model that combines biopharmaceutical projects with digital health solutions.
Building on a Proven Track Record
Asabys, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, has already invested in 13 companies across its first fund, with one exit reported. The firm’s current assets under management (AUM) stand at nearly €120 million, according to its 2026 filings. The new fund’s structure mirrors the success of its initial venture, which saw significant participation from the European Investment Fund and other institutional backers.
“This first closing consolidates our position as a leading healthtech investor in Southern Europe,” said Clara Campàs, co-founder of Asabys. “The growing interest from investors underscores the potential of private capital in driving healthcare innovation.”
Strategic Partnerships and Market Positioning
Banc Sabadell’s continued role as a key investor highlights the firm’s alignment with institutional players seeking high-growth opportunities in the healthtech sector. Alantra, a strategic partner since Asabys’ launch, has also reinforced its commitment to the new fund. These partnerships bolster Asabys’ ability to identify and scale disruptive technologies, particularly in areas like advanced diagnostics and medical devices.
The firm’s focus on “solid scientific evidence” aligns with broader trends in venture capital, where investors prioritize projects with measurable patient outcomes. SAHII 2’s mandate to support solutions addressing unmet medical needs positions it to capitalize on the EU’s growing emphasis on digital health adoption.
Implications for the European Healthtech Ecosystem
Asabys’ expansion comes amid increased funding for health innovation across Europe. The European Commission’s Horizon Europe program and national initiatives like Spain’s Centre for Technological Development and Innovation (CDTI) have created a fertile environment for startups. While the firm’s latest fund does not explicitly reference CDTI or the European Investment Fund (EIF), its
Keep reading
